Alembic Pharma gets USFDA tentative nod for generic of Rexulti

Alembic Pharma gets USFDA tentative nod for generic of Rexulti

It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia

FPJ Web DeskUpdated: Thursday, March 09, 2023, 10:25 AM IST
article-image
Alembic Pharma gets USFDA tentative nod for generic of Rexulti | Image: Wikipedia (Representative)

Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.

The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.

It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.

According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.

The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.

RECENT STORIES

Zepto Raises $665 Million; Valuation Nearly Triples To $3.6 Billion

Zepto Raises $665 Million; Valuation Nearly Triples To $3.6 Billion

'I Get Knocked Down, But...': Paytm Founder Vijay Shekhar Sharma Shares Resilience Amid RBI...

'I Get Knocked Down, But...': Paytm Founder Vijay Shekhar Sharma Shares Resilience Amid RBI...

Starlink Introduces The Mini Version Of Satellight Internet For Travelers

Starlink Introduces The Mini Version Of Satellight Internet For Travelers

Indian Jewellery Sector Revenue Shoots Up By Over ₹1 Lakh Crore In 5 Years: Report

Indian Jewellery Sector Revenue Shoots Up By Over ₹1 Lakh Crore In 5 Years: Report

Nikkei, Hang Seng, Sensex Down: Major Asian Indices Trade In Red

Nikkei, Hang Seng, Sensex Down: Major Asian Indices Trade In Red